2. Search Result
Search Result
Results for "

ASCVD

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18778
    Obicetrapib

    TA-8995; DEZ-001; AMG-899

    		 CETP Apolipoprotein LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib
  • HY-173322
    Lp(a)-IN-8

    		LPL Receptor Cardiovascular Disease
    Lp(a)-IN-8 (compound 15) is an Lp(a) inhibitor. Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) .
    Lp(a)-IN-8
  • HY-W709553
    Glyceryl Triformate
    1 Publications Verification

    Triglyceride

    		 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    Glyceryl Triformate (Triglyceride) is the major form of storage and transport of fatty acids within cells and in the plasma. Glyceryl Triformate forms lipoproteins with cholesterol ester, and participates in the blood circulation. Glyceryl Triformate can lead to hypertriglyceridemia (HTG), which increases the risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis .
    Glyceryl Triformate
  • HY-158825
    Cepadacursen sodium

    CIVI007 sodium

    		 PCSK9 Metabolic Disease
    Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia research and the prevention of atherosclerotic cardiovascular disease (ASCVD).
    Cepadacursen sodium
  • HY-18778A
    Obicetrapib sodium

    TA-8995 sodium; DEZ-001 sodium; AMG-899 sodium

    		 Apolipoprotein CETP LPL Receptor LDLR Cardiovascular Disease
    Obicetrapib (TA-8995; DEZ-001) sodium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib sodium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib sodium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib sodium
  • HY-18778B
    Obicetrapib potassium

    TA-8995 potassium; DEZ-001 potassium; AMG-899 potassium

    		 Apolipoprotein CETP LPL Receptor LDLR Metabolic Disease
    Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: